Business Wire

G42, OceanX, G-Tech and the Indonesian Government to Collaborate to Advance Oceanic Research to Protect the Marine Environment

18.11.2022 20:10:00 EET | Business Wire | Press release

Share

G42, the leading UAE-based AI and cloud computing company and global nonprofit ocean exploration organization OceanX, along with G-Tech Digital Asia (G-Tech), and the Government of the Republic of Indonesia via its Coordinating Ministry for Maritime Affairs and Investment (CMMAI) have announced the signing of a Letter of Intent to establish a collaboration to develop ocean research to help protect the marine environment.

In furtherance of this proposed collaboration, G42 intends to deploy G42 Cloud’s large-scale cloud infrastructure and services, remote sensing drone systems by Bayanat, a public listed company at ADX in which G42 owns a majority stake, and cutting-edge marine genomics applications by G42 Healthcare in the support of OceanX’s social welfare mission and its world-class marine research and media vessel the R/V OceanXplorer, to conduct advanced, in-depth analysis of the coastal and oceanic environments.

The Letter of Intent was signed by Mohammad Firman Hidayat, Acting Deputy Coordinating Minister for Maritime Resources, Peng Xiao, Group CEO of G42, Vincent Pieribone, Vice Chairman of OceanX and Michel Hamilton, CEO of G-Tech.

The collaboration will support the aims of the Indonesian government, led by CMMAI, to improve management of marine resources including biodiversity and conservation of ecosystems, through the use of new technology and methodologies and OceanX’s broader mission to explore the ocean and bring it back to the world through educational media.

The project recognizes the importance of detailed mapping of marine resources through advanced technologies in order to protect and preserve the ocean environment and the livelihoods of the communities that are reliant on it. G42 will support OceanX and CMMAI research with a focus on mapping fisheries and marine resources through data-driven e-DNA, socio-economic, and ecological characters in coastal-marine ecosystems. The proposed collaboration also includes training and knowledge transfer to build human capacity and supporting infrastructure for CMMAI.

In line with the UAE’s mandate to explore and leverage advanced technologies to spearhead the efforts towards environmental preservation, G42 is deploying its extensive portfolio of companies to develop new and better ways in which both public and private organizations can address some of the most pressing climate and environmental challenges.

Peng Xiao, Group CEO of G42 commented: “We are proud to be collaborating with CMMAI and OceanX on this project to develop a greater understanding of Indonesia’s marine environment. Better data is vital to developing a more holistic view of our oceans’ condition, and through our work with OceanX, we are looking to support the development of new, tailored solutions and technologies that will help local authorities to protect the marine environment, for the benefit of present and future generations.”

Dr. Prashanth Marpu, Director of Geospatial Centre Of Excellence and Climate Action Program at Bayanat said: “Oceans are highly complex environments, and monitoring and research can present many challenges to researchers and scientists working in this field. Bayanat is applying its expertise in real-time geospatial services and solutions and handling large-scale data to develop the tools that will allow the research community to leverage big data analysis of the maritime environment.”

About G42
G42 is a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating across the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.

G42 is driving change in the region and beyond, joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular medicine to space travel and everything in between, G42 realizes exponential possibilities, today.

For further information visit www.g42.ai.

About OceanX
Oceanographic Research & Exploration Foundation (OceanX) is a mission to support scientists to explore the ocean and to bring it back to the world through captivating media. Uniting leading media, science, and philanthropy partners, OceanX utilizes next-gen technology, fearless science, compelling storytelling, and immersive experiences to educate, inspire, and connect the world with the ocean and build a global community deeply engaged with understanding, enjoying, and protecting our oceans. OceanX is an initiative of Dalio Philanthropies, which furthers the diverse philanthropic interests of Dalio family members.

For more information visit www.oceanx.org and follow OceanX on Facebook, Instagram, Twitter, TikTok and LinkedIn.

About Bayanat
Bayanat, an ADX listed public company with majority shareholding by G42, provides comprehensive world-class AI-powered geospatial solutions to a growing number of sectors such as Defense, Environment, Energy & Resources, Smart Cities and Transportation. It’s offering includes topographic, hydrographic and aeronautical products and charts, as well as spatial data surveying, analysis, management, modelling, visualization and cartography services. Bayanat’s solutions harness vast amounts of premium and unique data from a range of sources including Satellites, High Altitude Pseudo Satellites (HAPS) and Earth Observation powered by AI to drive geospatial intelligence (gIQ).

For more information, please visit: www.bayanat.ai

Twitter:
https://twitter.com/bayanat_ai
LinkedIn:
https://www.linkedin.com/company/bayanatg42/
Instagram:
https://www.instagram.com/bayanat.g42/
Facebook:
https://www.facebook.com/bayanat.g42

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries, please send an email to: g42@trailrunnerint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye